All-stock deal raises shareholder dilution concerns despite strategic goal of creating a diversified semiconductor equipment leader.
First-of-its-kind maintenance therapy approved for extensive-stage small cell lung cancer, a historically difficult-to-treat malignancy.
The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Shares surge on massive volume after EPS Ventures announced its intention to acquire LNG shipping firm Cool Company.
A flurry of multi-billion dollar acquisitions by Pfizer, Genmab, and Axcelis signals renewed confidence and strategic positioning in high-growth sectors.
The deal paves the way for the integration of Monogram's advanced surgical robotics, with a closing date set for early October 2025.